2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Purity ≥98.0% Olaparib Intermediate Factory
Kuyera Kwambiri, Kupanga Zamalonda
Olaparib ndi Othandizira Ogwirizana:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl) piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Dzina la Chemical | 2-Fluoro-5-Formylbenzonitrile |
| Mawu ofanana ndi mawu | 3-Cyano-4-Fluorobenzaldehyde |
| Nambala ya CAS | 218301-22-5 |
| Nambala ya CAT | RF-PI451 |
| Stock Status | Mu Stock, Kupanga Kukula Mpaka Matani |
| Molecular Formula | C8H4FNO |
| Kulemera kwa Maselo | 149.12 |
| Melting Point | 80.0 mpaka 84.0 ℃ (lit.) |
| Kusungunuka | Zosungunuka mu Methanol |
| Mtundu | Ruifu Chemical |
| Kanthu | Zofotokozera |
| Maonekedwe | Ufa Wachikasu mpaka Woyera |
| Chiyero | ≥98.0% |
| Chinyezi (KF) | ≤0.50% |
| Zonse Zonyansa | ≤2.0% |
| Test Standard | Enterprise Standard |
| Kugwiritsa ntchito | Wapakatikati wa Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
Phukusi: Botolo, Aluminiyamu zojambulazo thumba, makatoni Drum, 25kg/ng'oma, kapena malinga ndi zofuna za kasitomala.
Mkhalidwe Wosungira:Sungani m'mitsuko yosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala ndi chinyezi.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) imagwiritsidwa ntchito pokonzekera mankhwala a heterocyclic monga PARP inhibitors kuti agwiritse ntchito mankhwala.2-Fluoro-5-Formylbenzonitrile imagwiritsidwa ntchito ngati pakati pa Olaparib (CAS: 763113-22-0).Olaparib ndi molekyu yaing'ono yoletsa PARP1/PARP2 (IC50: 5/1 nM) koma ndiyopanda mphamvu polimbana ndi PARP tankyrase-1 (IC50: 1.5 µM).Olaparib (AZD-2281, dzina lamalonda Lynparza) ndi mankhwala omwe amavomerezedwa ndi FDA a khansa, opangidwa ndi KuDOS Pharmaceuticals ndipo pambuyo pake ndi AstraZeneca.Ndi PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), puloteni yomwe imakhudzidwa ndi kukonza kwa DNA. Imalimbana ndi khansa mwa anthu omwe ali ndi masinthidwe amtundu wa BRCA1 kapena BRCA2, omwe amaphatikizapo khansa ya m'chiberekero, m'mawere, ndi prostate.Mu December 2014, olaparib inavomerezedwa kuti igwiritsidwe ntchito ngati wothandizira mmodzi ndi EMA ndi FDA.Chivomerezo cha FDA chili pa majeremusi a BRCA mutated (gBRCAm) khansa yapamwamba ya ovarian yomwe yalandira mizere itatu kapena kupitilira apo ya chemotherapy.
